16th Apr 2026 A plain language summary looking at nivolumab + chemotherapy for Asian people with advanced/recurrent stomach or gastroesophageal cancer
16th Apr 2026 A plain language summary on the ELM-2 study: odronextamab for relapsed/refractory follicular lymphoma
25th Feb 2026 TASUKI-52 study of combination therapy using nivolumab, platinum chemotherapy, and bevacizumab for advanced or recurrent nonsquamous NSCLC: a plain language summary
25th Feb 2026 How the body handles lower-dose nilotinib tablet (Danziten™) versus capsule (Tasigna®): a plain language summary
25th Feb 2026 Plain language summary: DESTINY-Lung02 study of trastuzumab deruxtecan for HER2-mutant metastatic non-small-cell lung cancer
25th Feb 2026 Managing specific adverse effects of teclistamab in multiple myeloma patients: a plain language summary
25th Feb 2026 DESTINY-CRC02 trial results for trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary
22nd Jan 2026 AMPECT study on nab-sirolimus therapy for advanced malignant perivascular epithelioid cell tumors: a plain language summary
22nd Jan 2026 HARMONi-2 trial results comparing two treatments for PD-L1–positive non-small cell lung cancer: a plain language summary
22nd Jan 2026 Plain language summary: results of pre-transplant inotuzumab ozogamicin treatment in acute lymphoblastic leukemia patients
22nd Jan 2026 Plain language summary: The Phase II ENGOT-OV60/GOG-3052/RAMP 201 study of dual avutometinib-defactinib therapy in recurrent low-grade serous ovarian cancer
22nd Jan 2026 DESTINY-Gastric02 findings on trastuzumab deruxtecan in HER2-positive gastric cancer: plain language summary
22nd Jan 2026 EORTC 1333/PEACE-3 research on enzalutamide with or without radium-223 for advanced prostate cancer patients with bone metastases: a plain language summary
22nd Jan 2026 Patient treatment preferences for relapsed or refractory multiple myeloma: a plain language summary
28th Nov 2025 TROPION-Lung01 trial for non-small cell lung cancer treatment: a plain language summary
28th Nov 2025 Plain language summary: TROPiCS-04 study of sacituzumab govitecan in advanced urinary tract cancer
28th Oct 2025 ERICA study plain language summary: olanzapine for nausea in breast cancer patients on trastuzumab deruxtecan
28th Oct 2025 Plain language summary of POLARIS: real-world palbociclib effectiveness and life quality impact
28th Oct 2025 CEPHEUS study: daratumumab combination therapy for newly diagnosed multiple myeloma: plain language summary
28th Oct 2025 CheckMate 7FL trial: nivolumab versus placebo in estrogen-positive breast cancer treatment: plain language summary
23rd Oct 2025 Plain language summary of the IMerge Phase 3 study: imetelstat vs placebo in lower-risk myelodysplastic syndrome patients with anemia
19th Sep 2025 A plain language summary of the MonumenTAL-1 study: talquetamab for relapsed/ refractory multiple myeloma
19th Sep 2025 Plain language summary looking at palbociclib treatment for advanced breast cancer in older patients
15th Sep 2025 Plain language summary: testing sacituzumab govitecan in metastatic bladder cancer patients after immunotherapy when standard chemotherapy isn’t an option
15th Aug 2025 How isatuximab injections work when given under the skin to people with difficult-to-treat multiple myeloma: a plain language summary
18th Jul 2025 Plain language summary: the CHAPTER-GIST-301 study of pimitespib for treating late-stage digestive tract tumors
25th Jun 2025 Plain language summary: ECHELON-3 study results on using brentuximab vedotin combination therapy for diffuse large B-cell lymphoma patients
25th Jun 2025 Plain language summary: effectiveness and safety of larotrectinib in lung cancer patients with TRK fusion mutations – results from two trials
25th Jun 2025 Plain language summary: THOR Cohort 1 study findings on erdafitinib treatment compared to chemotherapy for patients with advanced urothelial cancer
24th Jun 2025 Plain language summary: two key studies on acalabrutinib’s efficacy and safety profile for treating patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
20th Jun 2025 Exploring encorafenib and binimetinib dosing options for BRAF V600-mutant melanoma with brain metastases: Plain language summary of the POLARIS study
11th Jun 2025 Plain language summary: Examining how loncastuximab tesirine performs after CAR T-cell treatment for diffuse large B-cell lymphoma in everyday practice
11th Jun 2025 Real-world results of sequential loncastuximab and CAR T-cell therapy in large B-cell lymphoma: plain language summary
27th May 2025 Plain language summary: The IPSOS study comparing atezolizumab versus standard chemotherapy for non-small cell lung cancer patients unsuitable for platinum treatment
27th May 2025 Plain language summary: comparing encorafenib plus cetuximab with chemotherapy vs standard treatments for BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study
27th May 2025 Plain language summary: Five-year results of nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer
20th May 2025 Plain language summary: EVOKE-01 study comparing sacituzumab govitecan vs docetaxel for lung cancer
20th May 2025 A plain language summary: MARIPOSA-2 study of amivantamab combinations for non-small-cell lung cancer
20th May 2025 A plain language summary: early STARBOARD study results for encorafenib, binimetinib and pembrolizumab in BRAF V600-mutant melanoma
13th May 2025 BEACON study reveals molecular patterns in BRAF-mutated colorectal cancer: plain language summary
13th May 2025 Plain language summary: how do race and income influence prostate cancer treatment choices in the United States?
13th May 2025 Real-world survival rates for advanced prostate cancer patients using abiraterone or enzalutamide treatments: a plain language summary
25th Apr 2025 Plain language summary of how the order of ALK treatments affects lung cancer patients in everyday life
25th Apr 2025 Plain language summary of first-line treatment with amivantamab-lazertinib for high-risk EGFR-positive lung cancer from the MARIPOSA study
22nd Apr 2025 Plain language summary: Palbociclib plus an aromatase inhibitor for HR+/HER2– metastatic breast cancer with lung or liver spread
22nd Apr 2025 Plain language summary of the MAGNITUDE study on niraparib and abiraterone treatment for advanced prostate cancer
